Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Kalvista Pharmaceuticals Inc
(NQ:
KALV
)
10.06
-0.03 (-0.30%)
Streaming Delayed Price
Updated: 1:00 PM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Kalvista Pharmaceuticals Inc
< Previous
1
2
3
Next >
Stocks That Hit 52-Week Lows On Wednesday
October 05, 2022
Wednesday saw 127 companies set new 52-week lows.
Via
Benzinga
Where KalVista Pharma Stands With Analysts
October 05, 2022
Analysts have provided the following ratings for KalVista Pharma (NASDAQ:KALV) within the last quarter:
Via
Benzinga
Why Is KalVista Pharmaceuticals (KALV) Stock Down 50% Today?
October 04, 2022
KALV stock investors are having a hard day as KalVista Pharmaceuticals just hit the brakes on a crucial clinical study.
Via
InvestorPlace
KalVista Shares Plunge After Ending KVD824 HAE Trial Over Elevated Liver Enzymes In Patients
October 04, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
October 19, 2022
On Wednesday, 200 companies hit new 52-week lows.
Via
Benzinga
Tesla To $370? Plus HC Wainwright Slashes PT On This Stock By 67%
October 06, 2022
HC Wainwright & Co. cut KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) price target from $48 to $16. KalVista Pharmaceuticals shares fell 1.8% to $5.06 in pre-market trading.
Via
Benzinga
Expert Ratings for KalVista Pharma
October 05, 2022
KalVista Pharma (NASDAQ:KALV) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Why KalVista Pharmaceuticals Shares Are Trading Lower By 59%; Here Are 89 Biggest Movers From Yesterday
October 05, 2022
Losers
Via
Benzinga
S&P 500 Rises 100 Points; Nasdaq Up 3%
October 04, 2022
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 300 points on Tuesday.
Via
Benzinga
KalVista Pharma: Q1 Earnings Insights
September 08, 2022
KalVista Pharma (NASDAQ:KALV) reported its Q1 earnings results on Thursday, September 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 04, 2022
Gainers
Via
Benzinga
Kalvista Crashes Nearly 60% After Adding HAE Drug To The Scrap Heap
October 04, 2022
The company scrapped its hereditary angioedema drug due to safety issues.
Via
Investor's Business Daily
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session
October 04, 2022
Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
October 04, 2022
On Tuesday, 44 companies hit new 52-week lows.
Via
Benzinga
Nasdaq Surges 350 Points; Crude Oil Rises Sharply
October 04, 2022
U.S. stocks traded higher midway through trading, with the Nasdaq Composite climbing more than 350 points on Tuesday.
Via
Benzinga
FaZe Holdings, AXT And Some Other Big Stocks Moving Lower On Tuesday
October 04, 2022
U.S. stocks traded higher, with the Dow Jones gaining more than 700 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
US Stocks Open Higher As Dow Jumps 550 Points
October 04, 2022
U.S. stocks traded higher this morning, with the Dow Jones climbing more than 550 points on Tuesday.
Via
Benzinga
Why Kalvista Pharmaceuticals Shares Are Down Over 50%
October 04, 2022
Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares are trading lower by 52.42% to $6.78 Tuesday morning after the company announced it terminated the KOMPLETE phase 2 clinical trial for KVD824 for the...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 04, 2022
Gainers Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 37.7% to $15.85 during Tuesday's pre-market session. The company's market cap stands at $23.3 million.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
October 04, 2022
Good morning, investor! It's time for a breakdown of the biggest pre-market stock movers traders need to know about for Tuesday!
Via
InvestorPlace
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 23, 2022
Via
Benzinga
KalVista Shares Climb As Late-Stage Label Extension Study On Skin Disorder Candidate Kicks-off
August 23, 2022
KalVista Pharmaceuticals (NASDAQ: KALV) has initiated the KONFIDENT-S open label extension (OLE) study for its ongoing Phase 3 study of sebetralstat for the on-demand treatment of hereditary angioedema...
Via
Benzinga
Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried
August 22, 2022
Shares hit their lowest point since November on the FDA's decision in HAE.
Via
Investor's Business Daily
Recap: KalVista Pharmaceuticals Q4 Earnings
July 07, 2022
KalVista Pharmaceuticals (NASDAQ:KALV) reported its Q4 earnings results on Thursday, July 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
KalVista Pharmaceuticals: Q3 Earnings Insights
March 10, 2022
KalVista Pharmaceuticals (NASDAQ:KALV) reported its Q3 earnings results on Thursday, March 10, 2022 at 07:00 AM. Here's what investors need to know about the...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the...
Via
Talk Markets
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
KalVista Pharmaceuticals: Q2 Earnings Insights
December 09, 2021
KalVista Pharmaceuticals (NASDAQ:KALV) reported its Q2 earnings results on Thursday, December 9, 2021 at 06:30 AM. Here's what investors need to know about the...
Via
Benzinga
Why KalVista Pharmaceuticals' Stock Is Trading Higher Today
September 15, 2021
KalVista Pharmaceuticals (NASDAQ:KALV) shares are trading lower after the FDA notified the company that it has placed a clinical hold on its Phase 2 clinical trial of...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
November 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.